

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 May 2025 (01.05.2025)



(10) International Publication Number
WO 2025/090658 A3

(51) International Patent Classification:

C07D 231/14 (2006.01) C07D 413/12 (2006.01)
C07D 231/56 (2006.01) C07D 417/12 (2006.01)
C07D 401/12 (2006.01) C07D 487/04 (2006.01)
C07D 403/12 (2006.01) A61P 35/00 (2006.01)
C07D 405/12 (2006.01)

(21) International Application Number:

PCT/US2024/052642

(22) International Filing Date:

23 October 2024 (23.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/545,413 24 October 2023 (24.10.2023) US
63/674,639 23 July 2024 (23.07.2024) US

(71) Applicant: **TERREMOTO BIOSCIENCES, INC.**
[US/US]: 230 E. Grand Ave., Suite, 200, South San Francisco, California 94080 (US).

(72) Inventors: **YANG, Kin S.**; 230 E. Grand Ave., Suite, 200, South San Francisco, California 94080 (US). **CHU, Hang**; 230 E. Grand Ave., Suite, 200, South San Francisco, California 94080 (US). **REISBERG, Solomon H.**; 230 E. Grand Ave., Suite, 200, South San Francisco, California 94080 (US). **CHOY, Wai Yan**; 230 E. Grand Ave., Suite, 200, South San Francisco, California 94080 (US). **BEST-VATER, Brian P.**; 230 E. Grand Ave., Suite, 200, South San Francisco, California 94080 (US). **ZAJDLIK, Adam**; 230 E. Grand Ave., Suite, 200, South San Francisco, California 94080 (US). **SPEVAK, Wayne**; 230 E. Grand Ave., Suite, 200, South San Francisco, California 94080 (US).

(74) Agent: **PERLA, Luis et al.**; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(54) Title: REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF




FIG 1A





FIG 1B



(57) Abstract: In some aspects, the present disclosure provides compounds of Formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), or pharmaceutically acceptable salts thereof, for the modulation of CDK2. In another aspect, the present disclosure provides methods for the treatment of diseases or disorders mediated by CDK2, such as oncology indications, using compounds of Formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), or pharmaceutically acceptable salts thereof.

[Continued on next page]

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

19 June 2025 (19.06.2025)